In a large multicenter retrospective cohort study consisting of 6213 patients, Wang et al., 2021 reported that serum SEMA4C was present in 84.4% of breast cancer patients, compared to only 20.75% in other solid tumours, thereby highlighting its potential use as a diagnostic biomarker in BC [41]. The gene discussed is SEMA4C; the disease is breast cancer.